ESC Professional Premium Access

NNC6019-0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial

Topic: Infiltrative Myocardial Disease

Congress Presentation

About the speaker

Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)
48 presentations
28 followers

6 more presentations in this session

Incidence and factors associated with de novo atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis

Speaker: Doctor C. Fumagalli (Florence, IT)

Thumbnail

Transthyretin cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a single center experience

Speaker: Doctor L. Scudeler (Turin, IT)

Thumbnail

Change in echocardiography in patients with transthyretin amyloid cardiomyopathy with tafamidis treatment.

Speaker: Doctor M. Morioka (Kumamoto, JP)

Thumbnail

Valve disease in cardiac amyloidosis: an echocardiographic score

Speaker: Doctor A. Aimo (Pisa, IT)

Thumbnail

Global longitudinal strain and quantitative sensory testing in pre-symptomatic patients with mutation for transthyretin amyloidosis

Speaker: Associate Professor M. Losi (Naples, IT)

Thumbnail

Access the full session

Amyloidosis and aortic stenosis

Speakers: Professor M. Fontana, Doctor C. Fumagalli, Doctor L. Scudeler, Doctor M. Morioka, Doctor A. Aimo...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb